Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.00
+0.06 (0.86%)
At close: Mar 9, 2026, 4:00 PM EDT
7.00
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Kezar Life Sciences Employees
Kezar Life Sciences had 55 employees as of December 31, 2024. The number of employees decreased by 3 or -5.17% compared to the previous year.
Employees
55
Change (1Y)
-3
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,121,909
Market Cap
51.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Acrivon Therapeutics | 78 |
| LeonaBio | 26 |
| MiNK Therapeutics | 23 |
| Plus Therapeutics | 21 |
| Edesa Biotech | 17 |
| Nutriband | 13 |
| Alterity Therapeutics | 9 |
KZR News
- 2 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 4 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 4 months ago - Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 - Business Wire
- 5 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire
- 6 months ago - Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 7 months ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 8 months ago - Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire
- 10 months ago - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire